CARD11在弥漫大B细胞淋巴瘤中的表达及其预后意义

OBJECTIVE: To determine the CARD11 expression and its prognostic value in diffuse large B cell lymphoma (DLBCL). METHODS: This retrospective study included previously untreated patients diagnosed with DLBCL from January 2007 to December 2012. Formalin-fixed, paraffin-embedded blocks of these patients were collected. Tissue microarray was built and expression of CARD11 was examined immunohistochemically. Subtype of DLBCL was determined by Hans algorithm (CD10, BCL6, MUM1). The pattern of CARD11 was further studied and their correlation with outcome was analyzed. RESULTS: 79 patients with DLBCL were enrolled and two reactive lymph nodes were used as control. The positive rate of high CARD11 expression in DLBCL was 65.33%, which showed no significant associations with patients' characteristics. Positive CARD11 expression was associated with an inferior event free survival (EFS) (2-year EFS: 52.03% vs 86.12%,P=0.036). Even in patients with a high international prognostic index (IPI, 3–5 points), this difference still remained significant (Median EFS not reached vs 557 days, P=0.033). CONCLUSION: DLBCL patients with high CARD11 expression had a shorter EFS compared with low level of CARD11. This difference remained significant when patients were in high IPI (3–5 points), which might indicate the value of CARD11 in stratification of high-risk DLBCL patients.